COL18A1 and non-small cell lung carcinoma: Rh-endostatin used in the present study is a modified form of endostatin with an additional nine-amino acid sequence which formed another his-tag structure and has been approved for clinical use by the State Food and Drug Administration in China for the treatment of advanced non-small-cell lung cancer in 2005 [18].